Clinical trial
Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With…
NCT00182663 · Fred Hutchinson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00182663 |
|---|---|
| Title | Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant |
| Official title | Maintenance Therapy With Thalidomide, Dexamethasone and Clarithromycin (Biaxin) Following Autologous/Syngeneic Transplant for Multiple Myeloma |
| Lead sponsor | Fred Hutchinson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma |
| Intervention type | Drug |
| Interventions | clarithromycin, thalidomide, dexamethasone |
| Enrollment | 30 |
| Start date | Jun 1, 2003 |
| Primary completion | Apr 1, 2007 |
| First posted | Sep 16, 2005 |
| Last update posted | Jun 26, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: